Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

remedyrepack inc. - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 1000 mg - metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. important limitations of use metformin hydrochloride extended-release tablets should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. metformin hydrochloride extended-release tablets are contraindicated in patients with:metformin hydrochloride extended-release tablets are contraindicated in patients with: - severe renal impairment (egfr below 30ml/min/1.73 m 2 )  [see warnings and precautions ( 5.1)] . severe renal impairment (egfr below 30ml/min/1.73 m 2 )  [see warnings and precautions ( 5.1)] . - known hypersensitivity to metformin hydrochloride. known hypersensitivity to metformin hydrochloride. - acute or chronic metabolic acidosis, including diabetic ketoacidosis. diabetic ketoacidosis should be treated with insulin. acute or chronic m

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; phenol; metacresol; zinc; dibasic sodium phosphate dihydrate; arginine; hydrochloric acid; sodium hydroxide; water for injections; nicotinamide - treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; phenol; metacresol; zinc; dibasic sodium phosphate dihydrate; arginine; hydrochloric acid; sodium hydroxide; water for injections; nicotinamide - treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; phenol; metacresol; zinc; dibasic sodium phosphate dihydrate; arginine; hydrochloric acid; sodium hydroxide; water for injections; nicotinamide - treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 1128.6 microgram (equivalent: pasireotide, qty 900 microgram) - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; tartaric acid - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 376.2 microgram (equivalent: pasireotide, qty microgram) - injection, solution - excipient ingredients: water for injections; mannitol; tartaric acid; sodium hydroxide - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 752.4 microgram (equivalent: pasireotide, qty 600 microgram) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; tartaric acid; mannitol - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ustekinumab, quantity: 90 mg - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; sucrose; water for injections; polysorbate 80; histidine - plaque psoriasis,adults - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,paediatric population, 6 years and older - stelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,psoriatic arthritis (psa),stelara, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological dmard therapy has been inadequate.,crohn?s disease,stelara is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,ulcerative colitis,stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - ustekinumab, quantity: 45 mg - injection, solution - excipient ingredients: histidine; polysorbate 80; histidine hydrochloride monohydrate; water for injections; sucrose - plaque psoriasis,adults - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,paediatric population, 6 years and older - stelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,psoriatic arthritis (psa),stelara, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological dmard therapy has been inadequate.,crohn?s disease,stelara is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,ulcerative colitis,stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 377.5 g (equivalent: iodine, qty 175 g) - injection, solution - excipient ingredients: trometamol; hydrochloric acid; water for injections; sodium calcium edetate - the medicinal product is for diagnostic use only intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography.,oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), hemiography, hysterosalpingography, and in adults, children and premature babies for studies of the gastrointestinal tract.,intrathecal: onmipaque is indicated for lumbar, thoracic, cervical and total columnar myelography and in computerised tomography of the cns in adults and children.